rs4562997 — SMAD3

SMAD3 rs4562997 — The Second TGF-beta Enhancer Switch

SMAD3 is the central intracellular signal transducer of TGF-beta (transforming growth factor-beta)¹¹ TGF-beta (transforming growth factor-beta)
A pleiotropic cytokine that governs immune tolerance, Treg differentiation, and mucosal homeostasis; when TGF-beta binds its receptor, SMAD2 and SMAD3 are phosphorylated and translocate to the nucleus to regulate target genes, the master pathway governing regulatory T cell (Treg) differentiation and immune tolerance. In immune cells, SMAD3 is required for Foxp3 expression — the transcription factor that defines Tregs — and for restraining both Th2 (allergic) and Th17 (autoimmune mucosal) lineages. rs4562997 is a second intronic enhancer variant in SMAD3, located at chromosome 15q22.33 (position 67,165,814 on GRCh38), roughly 15.5 kilobases downstream from the first confirmed enhancer variant, rs17293632. Together they constitute two independently validated regulatory control points for SMAD3 expression in immune-relevant tissues.

The Mechanism

Functional luciferase reporter assays²² Functional luciferase reporter assays
Reporter assays in which the variant sequence drives expression of a luminescent protein, enabling direct quantification of allele-specific transcriptional activity in thyroid cancer cell lines (TPC-1 and BCPAP) confirmed that both rs4562997 and rs17293632 regulate SMAD3 transcription through allele-specific enhancer elements located within SMAD3 introns. The two enhancers act independently — each drives SMAD3 expression based on the allele present at that position — meaning the combined haplotype state of both variants determines the net SMAD3 expression level in cells where these enhancers are active. While the Wang et al. 2018 study was conducted in the context of thyroid cancer susceptibility at the 15q22 locus, the enhancer regulatory mechanism is cell-type and context dependent: the same enhancer elements are active in immune cells, where SMAD3 expression governs Treg competency. Both alleles at rs4562997 produce measurably different transcriptional outputs (p<0.01 to p<0.001 in reporter assays), confirming the variant is not a passenger polymorphism but a true functional regulatory element.

The SMAD3 locus at 15q22 has been fine-mapped in IBD GWAS³³ fine-mapped in IBD GWAS
Fine-mapping identifies the most likely causal variant(s) within an associated region by computing posterior probabilities across all variants in strong LD to two independent association signals, consistent with the existence of at least two functional regulatory variants in this region. This dual-signal architecture maps precisely to the two confirmed enhancers at rs17293632 and rs4562997.

The Evidence

The Ferreira et al. 2017 Nature Genetics study⁴⁴ Ferreira et al. 2017 Nature Genetics study of 360,838 participants identified the SMAD3 locus as one of 136 genome-wide significant risk loci for allergic disease, with pleiotropic effects across asthma, hay fever, and eczema. The same locus appears in Crohn's disease GWAS by Franke et al. 2010⁵⁵ Crohn's disease GWAS by Franke et al. 2010 in a meta-analysis of six datasets (6,333 cases, 15,056 controls discovery phase; 29,720 replication), confirming SMAD3 among 71 established Crohn's susceptibility genes. This dual appearance in both allergic and autoimmune GWAS is the hallmark of the immune tolerance axis: SMAD3 impairment allows both Th2 (allergic) and Th17 (mucosal autoimmune) responses to escape restraint.

For the partner variant rs17293632, O'Donnell et al. 2019⁶⁶ O'Donnell et al. 2019 in a North American Crohn's cohort of 1,495 patients found that SMAD3 was among eight susceptibility variants associated with accelerated progression to abdominal surgery (P<0.05), suggesting SMAD3 functional status influences disease course, not just susceptibility. The Brylak et al. 2025 pediatric IBD study⁷⁷ Brylak et al. 2025 pediatric IBD study in 286 Polish children observed SMAD3 genotype-associated differences in corticosteroid requirements in Crohn's disease. rs4562997 is the second functional variant contributing to the same regulatory program, and individuals carrying risk alleles at both enhancer positions are expected to have more substantially reduced SMAD3 expression than either variant alone would predict. Direct clinical outcome data specific to rs4562997 are not yet available independently of rs17293632.

Practical Actions

The A allele at rs4562997 marks reduced SMAD3 enhancer activity at this second regulatory element. As with rs17293632, the clinical consequence is not deterministic — most carriers remain disease-free — but the allele reduces SMAD3-mediated immune tolerance capacity, lowering the threshold for both allergic sensitization and mucosal inflammation. The gut microbiome is the most tractable environmental modifier: short-chain fatty acids (SCFAs) from fiber fermentation, particularly butyrate, reinforce Foxp3+ Treg differentiation through SMAD3-dependent pathways and can partially compensate for reduced baseline SMAD3 enhancer activity. Fiber diversity (30+ plant species per week) predicts microbiome richness and SCFA production more reliably than total fiber quantity alone.

Carriers of the AA genotype who also carry the rs17293632 T allele face compounding SMAD3 expression reduction across two independent enhancers — the combined haplotype effect is likely greater than either variant alone, warranting more proactive gut health monitoring.

Interactions

rs4562997 and rs17293632 are both confirmed allele-specific SMAD3 enhancers located within the same gene, ~15.5 kb apart. Their combined haplotype state determines net SMAD3 expression in enhancer-active tissues, including immune cells. Carriers of risk alleles at both positions (A at rs4562997, T at rs17293632) may have more substantially impaired TGF-beta–SMAD3 signaling than either variant predicts individually. The SMAD3 pathway also intersects with IL-10 (rs1800795) signaling — IL-10 cooperates with TGF-beta for mucosal tolerance — so risk alleles in both pathways compound gut mucosal vulnerability.